Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Influence of metabolic state and body composition on the action of pharmacological treatment of migraine

N. Bruijn, R. van Lohuizen, M. Boron, M. Fitzek, F. Gabriele, G. Giuliani, L. Melgarejo, P. Řehulka, G. Sebastianelli, P. Triller, S. Vigneri, B. Özcan, AM. van den Brink, European Headache Federation School of Advanced Studies (EHF‐SAS)

. 2024 ; 25 (1) : 20. [pub] 20240213

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007149

Migraine is a disabling neurovascular disorder among people of all ages, with the highest prevalence in the fertile years, and in women. Migraine impacts the quality of life of affected individuals tremendously and, in addition, it is associated with highly prevalent metabolic diseases, such as obesity, diabetes mellitus and thyroid dysfunction. Also, the clinical response to drugs might be affected in patients with metabolic disease due to body composition and metabolic change. Therefore, the efficacy of antimigraine drugs could be altered in patients with both migraine and metabolic disease. However, knowledge of the pharmacology and the related clinical effects of antimigraine drugs in patients with metabolic disease are limited. Therefore, and given the clinical relevance, this article provides a comprehensive overview of the current research and hypotheses related to the influence of metabolic state and body composition on the action of antimigraine drugs. In addition, the influence of antimigraine drugs on metabolic functioning and, vice versa, the influence of metabolic diseases and its hormonal modulating medication on migraine activity is outlined. Future exploration on personalizing migraine treatment to individual characteristics is necessary to enhance therapeutic strategies, especially given its increasing significance in recent decades.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007149
003      
CZ-PrNML
005      
20240423155742.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s10194-024-01724-3 $2 doi
035    __
$a (PubMed)38347465
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Bruijn, Noor $u Department of Internal Medicine, Division of Vascular Medicine and Pharmacology, Erasmus MC, Erasmus University Medical Center Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
245    10
$a Influence of metabolic state and body composition on the action of pharmacological treatment of migraine / $c N. Bruijn, R. van Lohuizen, M. Boron, M. Fitzek, F. Gabriele, G. Giuliani, L. Melgarejo, P. Řehulka, G. Sebastianelli, P. Triller, S. Vigneri, B. Özcan, AM. van den Brink, European Headache Federation School of Advanced Studies (EHF‐SAS)
520    9_
$a Migraine is a disabling neurovascular disorder among people of all ages, with the highest prevalence in the fertile years, and in women. Migraine impacts the quality of life of affected individuals tremendously and, in addition, it is associated with highly prevalent metabolic diseases, such as obesity, diabetes mellitus and thyroid dysfunction. Also, the clinical response to drugs might be affected in patients with metabolic disease due to body composition and metabolic change. Therefore, the efficacy of antimigraine drugs could be altered in patients with both migraine and metabolic disease. However, knowledge of the pharmacology and the related clinical effects of antimigraine drugs in patients with metabolic disease are limited. Therefore, and given the clinical relevance, this article provides a comprehensive overview of the current research and hypotheses related to the influence of metabolic state and body composition on the action of antimigraine drugs. In addition, the influence of antimigraine drugs on metabolic functioning and, vice versa, the influence of metabolic diseases and its hormonal modulating medication on migraine activity is outlined. Future exploration on personalizing migraine treatment to individual characteristics is necessary to enhance therapeutic strategies, especially given its increasing significance in recent decades.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a kvalita života $7 D011788
650    12
$a migréna $7 D008881
650    _2
$a obezita $7 D009765
650    _2
$a složení těla $7 D001823
650    12
$a metabolické nemoci $x farmakoterapie $7 D008659
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a van Lohuizen, Romy $u Department of Internal Medicine, Division of Vascular Medicine and Pharmacology, Erasmus MC, Erasmus University Medical Center Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
700    1_
$a Boron, Malgorzata $u Department of Neurology, University Hospital, Wroclaw Medical University, Wroclaw, Poland
700    1_
$a Fitzek, Mira $u Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany
700    1_
$a Gabriele, Francesca $u Department of Applied Clinical Sciences and Biotechnology, Neuroscience Section, University of L'Aquila, L'Aquila, Italy
700    1_
$a Giuliani, Giada $u Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy
700    1_
$a Melgarejo, Laura $u Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain
700    1_
$a Řehulka, Pavel $u St. Anne's University Hospital, Faculty of Medicine Masaryk University Czech Republic, Brno, Czech Republic
700    1_
$a Sebastianelli, Gabriele $u Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino ICOT, Latina, Italy
700    1_
$a Triller, Paul $u Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany
700    1_
$a Vigneri, Simone $u Casa Di Cura Santa Maria Maddalena, Neurology and Neurophysiology Service, Occhiobello, Italy
700    1_
$a Özcan, Behiye $u Department of Internal Medicine, Division of Vascular Medicine and Pharmacology, Erasmus MC, Erasmus University Medical Center Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
700    1_
$a van den Brink, Antoinette Maassen $u Department of Internal Medicine, Division of Vascular Medicine and Pharmacology, Erasmus MC, Erasmus University Medical Center Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands. a.vanharen-maassenvandenbrink@erasmusmc.nl
710    2_
$a European Headache Federation School of Advanced Studies (EHF‐SAS)
773    0_
$w MED00005758 $t The Journal of headaches and pain $x 1129-2377 $g Roč. 25, č. 1 (2024), s. 20
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38347465 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155739 $b ABA008
999    __
$a ok $b bmc $g 2081252 $s 1216916
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 25 $c 1 $d 20 $e 20240213 $i 1129-2377 $m The Journal of headaches and pain $n J Headache Pain $x MED00005758
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace